About This Presentation



Read here the market research report on the “Still’s Disease Treatment Market" published by CMI Team – PowerPoint PPT presentation

Number of Views:40


Transcript and Presenter's Notes


  • Coherent Market Insights
  • Market Research and Business Consulting Services
  • https//
  • COVID-19 Impact Tracker

  • Stills Disease Treatment Market, by Treatment
    (Pain Management, Corticosteroids, Tocilizumab,
    Canakinumab, Anakinra, and Others), by Route of
    Administration (Injectable and Oral), by
    Distribution Channel (Retail Pharmacies, Hospital
    Pharmacies, and Online Pharmacies), and by Region
    (North America, Latin America, Europe, Asia
    Pacific, Middle East, and Africa) - Size, Share,
    Outlook, and Opportunity Analysis, 2020 - 2027

  • Stills disease is a rare rheumatic condition.
    This condition is characterized by biological and
    clinical symptoms such as high spiking fever,
    joint swelling, muscle pain, sore throat,
    increased number of white cells (leukocytes,
    especially neutrophils), and biological
    hepatitis. Treatment for stills disease can be
    classified into 2 categories, namely symptomatic
    treatments and effective therapies. Symptomatic
    treatments can be initiated immediately, even
    when the diagnosis has not been established
    whereas, effective therapies are designed to
    treat the condition more efficiently to eradicate
    the symptoms of the disease.

  • According to a study published in The American
    Journal of Medicine, the treatment of stills
    disease has been largely derived from
    retrospective data and case reports. While mild
    cases can be treated with NSAIDs (Nonsteroidal
    Anti-inflammatory Drugs), more than 80 of
    stills disease patients need the use of
    corticosteroids and do not achieve remission.
    There is no such known risk factor that develops
    the Stills disease, however, it is assumed that
    it is caused due to over activation of IL-1
    (Interleukin-1) in the body.
  • The rising demand for specific new treatments and
    the emergence of drugs for stills disease are
    expected to drive the stills disease treatment
    market growth during the forecast period. For
    instance, as per the U.S. Food and Drug
    Administration (FDA), Canakinumab (Ilaris) can be
    indicated to all patients older than 2 years with
    Still's disease.

Stills Disease Treatment Market - Impact of
Coronavirus (Covid-19) Pandemic
  • Stills disease treatment market is hugely
    affected due to the outbreak of COVID-19, as it
    is becoming difficult for researchers to conduct
    researches during this pandemic situation. People
    with rheumatic diseases such as Still's disease
    are more prone to getting infected with the
    coronavirus. Thus, majority of the vendors are
    concentrating on developing strategies to help
    patients with stills disease to remain agile
    during the global disruptions due to COVID-19
    pandemic. In addition, many government bodies
    across the globe are taking decisions such as new
    regulations to deal with the current crisis.

  • The all-inclusive version of the report will
    include the impact of COVID-19 and the probable
    changes in the future outlook of the industry, by
    taking into account the technological, social,
    political, and economical parameters.
  • The stills disease treatment market is estimated
    to be valued at US 1,539.4 million in 2020 and
    is expected to rise at a CAGR of 4.49 during the
    forecast period (2020-2027).

Figure 1. Stills Disease Treatment Market Share
() Analysis, By Route of Administration, 2020
  • An increase in the number of mergers
    acquisitions and drug launches is expected to
    propel growth of the stills disease treatment
  • Key players in the market are involved in mergers
    acquisitions to develop advanced drugs and
    treatment, and launch them in the stills disease
    treatment market. The drug launches in the
    industry is estimated to significantly boost the
    market growth and create lucrative growth
    opportunities in the overall market during the
    forecast period.
  • For instance, in July 2018, SOBI launched a
    third-line treatment, Kineret drug for the
    treatment of adult-onset still's disease (AOSD).
    This new therapy is indicated when the patient
    does not respond to Disease-modifying
    antirheumatic drugs (DMARDs)  and
    corticosteroids, and fail to respond to
    methotrexate. The drug is currently available in
    the U.K. for Cryopyrin-associated periodic
    syndromes (CAPS) and rheumatoid arthritis (RA).

  • Furthermore, companies are adopting several
    strategies such as license agreements and
    partnerships to hold a strong position in the
    global industry. For instance, in July 2019, Aevi
    Genomic Medicine entered into a license agreement
    with AstraZeneca for phase II trials of MEDI2338,
    which is a fully human mAb (monoclonal antibody)
    that targets IL-18 (interleukin 18). The company
    has planned to initially develop MEDI2338 for
    AOSD (adult-onset Still's disease), which is a
    rare and orphan rheumatological disease with
    presently no approved biologic therapies in the

Stills Disease Treatment Market - Restraints
  • Unavailability of specific therapeutics for
    stills disease condition is considered to be one
    of the potential restraints affecting the market
    growth. For instance, the treatment for stills
    disease is directed towards the use of
    anti-inflammatory drugs such as aspirin and other
    nonsteroidal drugs (NSAIDs). In some cases,
    cortisone medications such as prednisone are used
    to treat the condition. Other factors such as
    increasing number of generic therapeutics,
    product recalls, and patent expiration of
    licenses various drugs are likely to hamper the
    market growth.

(No Transcript)
Stills Disease Treatment Market Regional
  • Europe region accounted for the largest share in
    the stills disease treatment market in 2019,
    owing to the increasing focus of key players on
    research development and European Commission
    (EC) approvals in the market. For instance, in
    April 2018, Swedish Orphan Biovitrum AB announced
    that Kineret (anakinra) is approved by the EC for
    the treatment of stills disease. Kineret is
    indicated for adults, children, adolescents, and
    infants aged 8 months and above with at least
    10kg bodyweight for the treatment of Stills
    disease. This also includes AOSD and SJIA with
    active systemic features of moderate to high
    disease activity.

  • The U.S. market followed the same. In June 2020,
    the U.S. FDA approved Switzerland-based
    Novartiss Ilaris injection for the treatment of
    active stills disease. This approval also
    includes treatment for Adult-Onset Stills
    Disease (AOSD). The Ilaris injection was formerly
    approved for SJIA (Systemic Juvenile Idiopathic
    Arthritis) in patients aged 2 years and above.
  • The Asia Pacific region is witnessing a promising
    growth in the global stills disease treatment
    market, owing to initiatives taken by key players
    and approvals for the treatment of adult stills
    disease. For instance, in May 2019, Chugai
    Pharmaceutical Co., Ltd., a subsidiary of F.
    Hoffmann-La Roche Ltd.  received expanded
    approval from the MHLA (Ministry of Health Labor
    and Welfare) in Japan for Actemra (tocilizumab)
    for the treatment of adult Stills disease.

  • Figure 2. Stills Disease Treatment Market Value
    (US Mn) Y-o-Y Growth (), 2017-2027

Global Stills Disease Treatment Market -
Competitive Landscape
  • Key players operating in the Stills disease
    treatment market include AB2 Bio Ltd., F.
    Hoffmann-La Roche Ltd, Novartis AG, Swedish
    Orphan Biovitrum AB, Jubilant Life Sciences Ltd,
    Vintage Labs, Hikma Pharmaceuticals PLC, Teva
    Pharmaceutical Industries Ltd, Mylan N.V.,
    Horizon Therapeutics plc, Sun Pharmaceutical
    Industries Ltd, Zydus Cadila, Amneal
    Pharmaceuticals LLC, Dr Reddy's Laboratories
    Ltd., and Fresenius Kabi AG.

  • Request Sample Report
  • Request Customization
  • Download PDF Brochure
  • Talk to Analyst
  • Buy Now
  • Reference https//

About Us
  • Coherent Market Insights is a global market
    intelligence and consulting organization focused
    on assisting our plethora of clients achieve
    transformational growth by helping them make
    critical business decisions.
  • What we provide
  • Customized Market Research Services
  • Industry Analysis Services
  • Business Consulting Services
  • Market Intelligence Services
  • Long term Engagement Model
  • Country Specific Analysis

Contact Us
  • Mr. Shah
  • Coherent Market Insights Pvt.Ltd.
  • Address 1001 4th Ave, 3200 Seattle, WA 98154,
  • Phone 1-206-701-6702
  • Email

  • Thank You!
  • Kindly follow CMI Social Media
    Profiles for the latest company updates
  • Facebook
  • Linkedin
  • Twitter
  • https//
Write a Comment
User Comments (0)